NEW YORK, June 14 (GenomeWeb News) - Aiming to increase content and throughput in angiogenesis research, Chip-Man Technologies' Cell-IQ continuous cell culturing platform will now be used with TCS CellWorks' AngioKit model, the companies said today.
Cell-IQ is a continuous cell-culturing platform that enables real-time analysis of morphological and physiological events in living cells, co-cultures, primary cells, and monolayer tissue models. Chip-Man claims the technology "learns to identify, follow and measure morphological change in individual cells without traditional labels or dyes."
TCS CellWorks' AngioKit, meantime, uses human cell-lines to offer a cell-based system that quantitatively assesses pro- and anti-angiogenic agents, the company said. The kit is provided in 24-well plate format and is suitable for low volume screening applications.
According to TCS CellWorks CEO Terry Cartwright, the alliance "raises our ability to track cell proliferation, migration and differentiation within a complex co-culture model to a new level."
Chip-Man CEO Juha Korpinen said: "We welcome the opportunity to work with TCS CellWorks. They have a range of products to which Cell-IQ will bring additional value."